Zheng Huan, Hong Shi-Cong, Yu Jie, Wen Xiu-Ying
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2014 Jul;34(7):846-52.
To observe the effect of Zhenqing Recipe (ZQR) on non-alcoholic fatty liver (NAFL), and the expression of hepatic salt-inducible kinase 1 (SIK1) and sterol-regulatory element binding protein-ic (SREBP-lc) in type 2 diabetes rats.
A rat model of type 2 diabetes was established by high fat/sucrose diet combined with intraperitoneal injection of small dose streptozotocin (STZ) . Modeled rats were randomly divided into the model group, the ZQR group, and the metformin group, 8 in each group. Eight rats were recruited as a normal control group. ZQR at the daily dose of 12 g crude drugs/kg was administered to rats in the ZQR group by gastrogavage. Metformin suspension at the daily dose of 150 mg/kg was administered to rats in the metformin group by gastrogavage. Equal volume of distilled water was administered to rats in the normal control group and the model group. All medication lasted for 12 weeks. The levels of fasting blood glucose (FBG), free fatty acid (FFA), serum triglyceride (TG), serum total cholesterol (TC), serum alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were detected. The body weight and wet liver weight were weighed, and the liver weight index calculated. The liver TG content was measured. The pathological changes of liver and the expression of SIK1 were observed by HE staining and immunohistochemistry. The mRNA and protein expression of SIK1 and SREBP-1c were detected using RT-PCR and Western blot.
Compared with the normal control group, FBG, FFA, TG, TC, ALT, AST, liver weight index, and liver TG contents significantly increased (P < 0.01); liver steatosis was severe, the mRNA and protein expression of SIK1 obviously decreased (P < 0.01); mRNA and protein expression of SREBP-1c increased (P < 0.01). After drug therapy, compared with the model group, FBG, FFA, TG, TC, ALT, AST, and liver weight index significantly decreased, liver TG contents significantly decreased, the mRNA and protein expression of SIK1 obviously increased, while mRNA and protein expression of SREBP-1c obviously decreased (P < 0.05, P < 0.01) in the ZQR group and the metformin group (P < 0.05, P < 0.01); and the pathological changes were also improved. All the indices were improved more in the ZQR group (all P < 0.05).
In this experiment, we found that the expression of SIK1 decreased in NAFL rats with type 2 diabetes. ZQR could alleviate lesion of NAFL type 2 diabetes rats possibly by up-regulating hepatic SIK1 expression at mRNA and protein levels.
观察贞清方(ZQR)对2型糖尿病大鼠非酒精性脂肪肝(NAFL)的影响,以及肝盐诱导激酶1(SIK1)和固醇调节元件结合蛋白-1c(SREBP-1c)的表达。
采用高脂/高糖饮食联合腹腔注射小剂量链脲佐菌素(STZ)建立2型糖尿病大鼠模型。将造模成功的大鼠随机分为模型组、贞清方组和二甲双胍组,每组8只。另取8只大鼠作为正常对照组。贞清方组大鼠按每日12 g生药/kg的剂量灌胃给予贞清方。二甲双胍组大鼠按每日150 mg/kg的剂量灌胃给予二甲双胍混悬液。正常对照组和模型组大鼠给予等体积蒸馏水。所有药物治疗持续12周。检测空腹血糖(FBG)、游离脂肪酸(FFA)、血清甘油三酯(TG)、血清总胆固醇(TC)、血清丙氨酸氨基转移酶(ALT)和天冬氨酸氨基转移酶(AST)水平。称取体重和肝脏湿重,计算肝脏重量指数。测定肝脏TG含量。采用HE染色和免疫组化观察肝脏病理变化及SIK1的表达。采用RT-PCR和Western blot检测SIK1和SREBP-1c的mRNA和蛋白表达。
与正常对照组比较,模型组大鼠FBG、FFA、TG、TC、ALT、AST、肝脏重量指数及肝脏TG含量显著升高(P < 0.01);肝脏脂肪变性严重,SIK1的mRNA和蛋白表达明显降低(P < 0.01);SREBP-1c的mRNA和蛋白表达升高(P < 0.01)。药物治疗后,与模型组比较,贞清方组和二甲双胍组大鼠FBG、FFA、TG、TC、ALT、AST及肝脏重量指数显著降低,肝脏TG含量显著降低,SIK1的mRNA和蛋白表达明显升高,而SREBP-1c的mRNA和蛋白表达明显降低(P < 0.